Specific genomic biomarkers can be used to identify glioma patients most likely to benefit from post-radiation chemotherapy and serve as a significant predictor of overall and progression-free survival, according to data published by researchers at The Ohio State University. Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
Patients with ALK-positive non-small cell lung cancer treated with ensartinib fared better and lived longer than those who received crizotinib, according to results of a phase III study.
The GioTag study demonstrated that sequential Gilotrif (afatinib) and osimertinib contributed to a median overall survival of nearly four years (47.6 months) among U.S. patients (129) with epidermal growth factor receptor mutation-positive (EGFR M+) non-small cell lung cancer and the common resistance mutation, T790M.
Researchers at Roswell Park Comprehensive Center found that people diagnosed with breast cancers that are small but invasive could benefit from hormone treatment. The findings were published in JAMA Network Open.
Researchers at the University of Kansas Medical Center have begun a study exploring an investigational drug, ATI-450, intended to fight the cytokine storm associated with COVID-19.
The University of Minnesota has begun a clinical study to test whether a novel cell therapy currently under clinical investigation as a treatment for acute myeloid leukemia and lymphoma can be effective as a treatment for COVID-19.
Tumor immunologist Patrick Hwu was named president and CEO of Moffitt Cancer Center. He will leave his job as the division head of Cancer Medicine at MD Anderson Cancer Center and begin his role at Moffitt Nov. 10.
Sylvester Comprehensive Cancer Center at the University of Miami Leonard M. Miller School of Medicine received a $120 million gift for cancer research. The donation is the single largest in the university's 95-year history.
Tracy Onega was named senior director of population sciences at Huntsman Cancer Institute and professor of population sciences at the University of Utah. She began her position at HCI Aug. 1.
Deirdre J. Cohen was named director of the Gastrointestinal Oncology Program for the Mount Sinai Health System, and Medical Director of the Cancer Clinical Trials Office at The Tisch Cancer Institute.
